熱門資訊> 正文
Harmony Biosciences与Lupin就Wakix仿制药上市达成协议
2025-06-05 22:54
- Lupin can launch a generic version of Harmony Biosciences' (NASDAQ:HRMY) Wakix (pitolisant) in January 2030 under a settlement agreement.
- The agreement resolves patent infringement litigation filed by Harmony against Lupin regarding its ANDA for generic Wakix, a treatment for excessive daytime sleepiness.
- Harmony noted that it is currently working on new formulations of pitolisant with utility patents that could provide exclusivity through 2044.
More on Harmony Biosciences Holdings, Inc.
- Harmony Biosciences Holdings, Inc. 2025 Q1 - Results - Earnings Call Presentation
- Harmony Biosciences Holdings, Inc. (HRMY) Q1 2025 Earnings Call Transcript
- Harmony Biosciences: A Compelling Risk-Reward Opportunity
- Harmony Biosciences projects $1B+ opportunity for WAKIX in narcolepsy by 2030
- Harmony Biosciences Holdings, Inc. Q1 2025 Earnings Preview
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
